NKGen Biotech to Present Integrated Phase 1 Clinical and Biomarker Analyses for Troculeucel in Alzheimer's Disease at AD/PD™ 2026

Core Insights - NKGen Biotech, Inc. is set to present new findings on its NK cell therapy, troculeucel, at the upcoming AD/PD™ 2026 conference, focusing on its cognitive benefits in Alzheimer's disease [1][3] Company Overview - NKGen Biotech is a clinical-stage biotechnology company specializing in the development of autologous and allogeneic NK cell therapeutics [9] - The company is headquartered in Santa Ana, California, and is focused on innovative treatments for neurodegenerative disorders and various cancers [9] Upcoming Presentations - NKGen will present an integrated analysis of patient-level data from two Phase 1 studies of troculeucel, assessing dose-response relationships and biomarker associations related to Alzheimer's disease [2] - The oral presentation titled "First-in-Class NK Cell Therapy Troculeucel Shows Cognitive Benefit in Moderate Alzheimer's: Dose Dependent Phase 1 Findings" is scheduled for March 21, 2026 [4] - A poster session titled "Plasma GFAP as a Biomarker for Anti-inflammatory Response and Cognitive Improvement in Phase 1 Trials of Troculeucel for Alzheimer's Disease" will take place from March 20-21, 2026 [5] Product Information - Troculeucel is a novel, patient-specific, ex vivo expanded autologous NK cell immunotherapeutic drug candidate, designated as SNK01 by the WHO [7][8] - The therapy aims to address neurodegenerative disorders and a wide range of cancers, marking a significant step in NKGen's journey toward market introduction [8]